Azithromycin in labour to reduce maternal and newborn sepsis and associated deaths: the need for a harmonized approach

Maternal and newborn infections are a major contributor to mortality morbidity globally. Lost-cost, effective safe interventions needed address these. Based on promising findings, azithromycin has been identified as potentially antibiotic reduce maternal in low- middle-income countries (LMICs). However, robust randomized clinical trials range of settings confirm these findings well understand the implications for antimicrobial resistance. To better impact health, at least three being conducted evaluate LMICs. We describe trials, importance harmonizing study measures potential public health LMICs.